140 related articles for article (PubMed ID: 17361071)
1. Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry.
Clerico A; Cappelli C; Ragni G; Caroli S; De Ioris MA; Sordi A; Petrucci F; Bocca B; Alimonti A
Ann Ist Super Sanita; 2006; 42(4):461-8. PubMed ID: 17361071
[TBL] [Abstract][Full Text] [Related]
2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
4. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
[TBL] [Abstract][Full Text] [Related]
6. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
9. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
Tonda ME; Murry DJ; Rodman JH
Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
11. Clinical, analytical and pharmacokinetic aspects in cancer chemotherapy with platinum coordination compounds.
Caroli S; Alimonti A; Petrucci F; La Torre F; Dominici C; Castello MA
Ann Ist Super Sanita; 1989; 25(3):487-97. PubMed ID: 2696394
[TBL] [Abstract][Full Text] [Related]
12. Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a rat model.
Pohlen U; Rieger H; Meyer BT; Loddenkemper C; Buhr HJ; Heitland P; Koester HD; Schneider P
Anticancer Res; 2007; 27(2):809-15. PubMed ID: 17465206
[TBL] [Abstract][Full Text] [Related]
13. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.
Brouwers EE; Tibben M; Rosing H; Schellens JH; Beijnen JH
Mass Spectrom Rev; 2008; 27(2):67-100. PubMed ID: 18231971
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
Chen CL; Sun MH; Tan DC; Liang LZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1405-8. PubMed ID: 15566645
[TBL] [Abstract][Full Text] [Related]
15. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.
Janssens T; Brouwers EE; de Vos JP; de Vries N; Schellens JH; Beijnen JH
Vet Comp Oncol; 2015 Jun; 13(2):124-32. PubMed ID: 23714139
[TBL] [Abstract][Full Text] [Related]
16. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparison between systemic and local chemotherapy by carboplatin in dogs.
Chen C; Wang W; Zhou H; Huang J; Liu P; Song T; Sun M
Reprod Sci; 2009 Nov; 16(11):1097-102. PubMed ID: 19657143
[TBL] [Abstract][Full Text] [Related]
18. Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field.
Spezia S; Bocca B; Forte G; Gatti A; Mincione G; Ronchi A; Bavazzano P; Alimonti A; Minoia C
Rapid Commun Mass Spectrom; 2005; 19(11):1551-6. PubMed ID: 15880656
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
